|
1
|
Zhang X, Ni Z, Duan Z, Xin Z, Wang H, Tan
J, Wang G and Li F: Overexpression of E2F mRNAs associated with
gastric cancer progression identified by the transcription factor
and miRNA co-regulatory network analysis. PLoS One.
10:e01169792015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen HZ, Tsai SY and Leone G: Emerging
roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev
Cancer. 9:785–797. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee BK, Bhinge AA and Iyer VR:
Wide-ranging functions of E2F4 in transcriptional activation and
repression revealed by genome-wide analysis. Nucleic Acids Res.
39:3558–3573. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Popov B, Chang LS and Serikov V: Cell
cycle-related transformation of the E2F4-p130 repressor complex.
Biochem Biophys Res Commun. 336:762–769. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Crosby ME, Jacobberger J, Gupta D, Macklis
RM and Almasan A: E2F4 regulates a stable G2 arrest response to
genotoxic stress in prostate carcinoma. Oncogene. 26:1897–1909.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee TA and Farnham PJ: Exogenous E2F
expression is growth inhibitory before, during, and after cellular
transformation. Oncogene. 19:2257–2268. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mott JL: MicroRNAs involved in tumor
suppressor and oncogene pathways: Implications for hepatobiliary
neoplasia. Hepatology. 50:630–637. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bertoli C, Skotheim JM and de Bruin RA:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Crijns AP, Fehrmann RS, de Jong S, Gerbens
F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de
Vries EG and van der Zee AG: Survival-related profile, pathways,
and transcription factors in ovarian cancer. PLoS Med.
6:e10000242009. View Article : Google Scholar
|
|
10
|
Chong JL, Wenzel PL, Saenz-Robles MT, Nair
V, Ferrey A, Hagan JP, Gomez YM, Sharma N, Chen HZ, Ouseph M, et
al: E2f1-3 switch from activators in progenitor cells to repressors
in differentiating cells. Nature. 462:930–934. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee EY, Cam H, Ziebold U, Rayman JB, Lees
JA and Dynlacht BD: E2F4 loss suppresses tumorigenesis in Rb mutant
mice. Cancer Cell. 2:463–472. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schwemmle S and Pfeifer GP: Genomic
structure and mutation screening of the E2F4 gene in human tumors.
Int J Cancer. 86:672–677. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Souza RF, Yin J, Smolinski KN, Zou TT,
Wang S, Shi YQ, Rhyu MG, Cottrell J, Abraham JM, Biden K, et al:
Frequent mutation of the E2F-4 cell cycle gene in primary human
gastrointestinal tumors. Cancer Res. 57:2350–2353. 1997.PubMed/NCBI
|
|
14
|
Khaleel SS, Andrews EH, Ung M, DiRenzo J
and Cheng C: E2F4 regulatory program predicts patient survival
prognosis in breast cancer. Breast Cancer Res. 16:4862014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fuchs B, Zhang K, Schabel A, Bolander ME
and Sarkar G: Identification of twenty-two candidate markers for
human osteogenic sarcoma. Gene. 278:245–252. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim EY, Jo JH and Lee MJ: Expressions of
E2F4 and E2F2 transcription factors in breast carcinoma. Korean J
Pathol. 39:301–306. 2005.
|
|
17
|
Enos M, Bancos SA, Bushnell I and Crispe
IN: E2F4 modulates differentiation and gene expression in
hemopoietic progenitor cells during commitment to the lymphoid
lineage. J Immunol. 180:3699–3707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma Y, Freeman SN and Cress WD: E2F4
deficiency promotes drug-induced apoptosis. Cancer Biol Ther.
3:1262–1269. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lassmann S, Weis R, Makowiec F, Roth J,
Danciu M, Hopt U and Werner M: Array CGH identifies distinct DNA
copy number profiles of oncogenes and tumor suppressor genes in
chromosomal- and microsatellite-unstable sporadic colorectal
carcinomas. J Mol Med (Berl). 85:293–304. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baxter E, Windloch K, Gannon F and Lee JS:
Epigenetic regulation in cancer progression. Cell Biosci. 4:452014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ng JM and Yu J: Promoter hypermethylation
of tumour suppressor genes as potential biomarkers in colorectal
cancer. Int J Mol Sci. 16:2472–2496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sabir M, Baig RM, Ali K, Mahjabeen I,
Saeed M and Kayani MA: Retinoblastoma (RB1) pocket domain mutations
and promoter hyper-methylation in head and neck cancer. Cell Oncol
(Dordr). 37:203–213. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ullah F, Khan T, Ali N, Malik FA, Kayani
MA, Shah Abbas ST and Saeed M: Promoter methylation status modulate
the expression of tumor suppressor (RbL2/p130) gene in breast
cancer. PLoS One. 10:e01346872015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ali A, Ullah F, Sabir AI, Faraz A, Khan M,
Shah Ali ST, Ali N and Saeed M: Aberrant promoter methylation at
CpG cytosines induce the upregulation of the E2F5 gene in breast
cancer. J Breast Cancer. 19:133–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee JT, Tsan WH and Chow KL: Simple
modifications to standard TRIzol® protocol allow
high-yield RNA extraction from cells on resorbable materials. J
Biomater Nanobiotechnol. 2:41–48. 2011. View Article : Google Scholar
|
|
28
|
Wang Y, Zhu W and Levy DE: Nuclear and
cytoplasmic mRNA quantification by SYBR green based real-time
RT-PCR. Methods. 39:356–362. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Strauss WM: Preparation of genomic DNA
from mammalian tissue. Curr Protoc Mol Biol: Chapter 2. 2001.
View Article : Google Scholar
|
|
31
|
Li LC and Dahiya R: MethPrimer: Designing
primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang D, Russell JL and Johnson DG: E2F4
and E2F1 have similar proliferative properties but different
apoptotic and oncogenic properties in vivo. Mol Cell Biol.
20:3417–3424. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bandara LR, Buck VM, Zamanian M, Johnston
LH and La Thangue NB: Functional synergy between DP-1 and E2F-1 in
the cell cycle-regulating transcription factor DRTF1/E2F. EMBO J.
12:4317–4324. 1993.PubMed/NCBI
|
|
34
|
Nevins JR: E2F: A link between the Rb
tumor suppressor protein and viral oncoproteins. Science.
258:424–429. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Beijersbergen RL, Kerkhoven RM, Zhu L,
Carlée L, Voorhoeve PM and Bernards R: E2F-4, a new member of the
E2F gene family, has oncogenic activity and associates with p107 in
vivo. Genes Dev. 8:2680–2690. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ginsberg D, Vairo G, Chittenden T, Xiao
ZX, Xu G, Wydner KL, DeCaprio JA, Lawrence JB and Livingston DM:
E2F-4, a new member of the E2F transcription factor family,
interacts with p107. Genes Dev. 8:2665–2679. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Le Cam L, Polanowska J, Fabbrizio E,
Olivier M, Philips A, Ng Eaton E, Classon M, Geng Y and Sardet C:
Timing of cyclin E gene expression depends on the regulated
association of a bipartite repressor element with a novel E2F
complex. EMBO J. 18:1878–1890. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhu WG, Srinivasan K, Dai Z, Duan W,
Druhan LJ, Ding H, Yee L, Villalona-Calero MA, Plass C and Otterson
GA: Methylation of adjacent CpG sites affects Sp1/Sp3 binding and
activity in the p21(Cip1) promoter. Mol Cell Biol. 23:4056–4065.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Almen MS, Nilsson EK, Jacobsson JA,
Kalnina I, Klovins J, Fredriksson R and Schiöth HB: Genome-wide
analysis reveals DNA methylation markers that vary with both age
and obesity. Gene. 548:61–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jin B and Robertson KD: DNA
methyltransferases, DNA damage repair, and cancer. Adv Exp Med
Biol. 754:3–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
